+

WO1999050295A3 - Analogues de proteine apparentee a l'agouti et leurs methodes d'utilisation - Google Patents

Analogues de proteine apparentee a l'agouti et leurs methodes d'utilisation Download PDF

Info

Publication number
WO1999050295A3
WO1999050295A3 PCT/US1999/006968 US9906968W WO9950295A3 WO 1999050295 A3 WO1999050295 A3 WO 1999050295A3 US 9906968 W US9906968 W US 9906968W WO 9950295 A3 WO9950295 A3 WO 9950295A3
Authority
WO
WIPO (PCT)
Prior art keywords
agouti
methods
related protein
agrp
analogues
Prior art date
Application number
PCT/US1999/006968
Other languages
English (en)
Other versions
WO1999050295A2 (fr
Inventor
Darren A Thompson
Jill Wilken
Ira Gantz
Stephen B H Kent
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Priority to AU39644/99A priority Critical patent/AU3964499A/en
Publication of WO1999050295A2 publication Critical patent/WO1999050295A2/fr
Publication of WO1999050295A3 publication Critical patent/WO1999050295A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des analogues de protéine apparentée à l'agouti (AGRP) et leurs méthodes d'utilisation. On peut prendre comme exemples de l'invention la synthèse chimique et le marquage détectable d'analogues d'AGRP, ainsi que leur nouvelle exploitation dans plusieurs dosages et criblages différents. On peut utiliser l'invention, par exemple, dans la découverte de médicaments et les diagnostics relatifs aux troubles de l'alimentation, y compris le syndrome de dépérissement, l'obésité et d'autres troubles relatifs à la régulation hypothalamique de l'alimentation.
PCT/US1999/006968 1998-03-30 1999-03-30 Analogues de proteine apparentee a l'agouti et leurs methodes d'utilisation WO1999050295A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39644/99A AU3964499A (en) 1998-03-30 1999-03-30 Agouti-related protein analogs and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7995798P 1998-03-30 1998-03-30
US60/079,957 1998-03-30

Publications (2)

Publication Number Publication Date
WO1999050295A2 WO1999050295A2 (fr) 1999-10-07
WO1999050295A3 true WO1999050295A3 (fr) 1999-11-18

Family

ID=22153903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006968 WO1999050295A2 (fr) 1998-03-30 1999-03-30 Analogues de proteine apparentee a l'agouti et leurs methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU3964499A (fr)
WO (1) WO1999050295A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030808A1 (fr) * 1999-10-27 2001-05-03 The Regents Of The University Of California Procedes et composes utiles pour moduler la liaison du recepteur de melanocortine-ligand
EP1125579A3 (fr) 2000-01-18 2003-01-02 Pfizer Products Inc. Utilisations de composés modulant la liaison entre l'AGRP et les récepteurs à la mélanocortine
AU2001261363A1 (en) * 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2003075742A2 (fr) * 2002-03-05 2003-09-18 Merck & Co., Inc. Marqueur biologique indiquant l'efficacite des medicaments coupe-faim
EP1753735A1 (fr) 2004-04-20 2007-02-21 Transtech Pharma, Inc. Derives de thiazole et de pyrimidine substitues, modulateurs des recepteurs de la melanocortine
US20110160128A1 (en) * 2008-03-28 2011-06-30 Qingyu Wu Corin for Treating Obesity and Diabetes
EP2320738A4 (fr) 2008-08-29 2011-08-24 Transtech Pharma Inc Dérivés d'aminothiazole substitués, compositions pharmaceutiques et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043412A1 (fr) * 1996-05-10 1997-11-20 Amgen Inc. Nouveau gene apparente a l'agouti
WO1997047316A1 (fr) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Procedes de selection pour des composes utiles dans la regulation du poids corporel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043412A1 (fr) * 1996-05-10 1997-11-20 Amgen Inc. Nouveau gene apparente a l'agouti
WO1997047316A1 (fr) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Procedes de selection pour des composes utiles dans la regulation du poids corporel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASKELL-LUEVANO C ET AL: "DISCOVERY OF PROTOTYPE PEPTIDOMIMETIC AGONISTS AT THE HUMAN MELANOCORTIN RECEPTORS MC1R AND MC4R", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 1997, pages 2133 - 2139, XP002910702, ISSN: 0022-2623 *
YANG ET AL.: "Characterization of Agouti-related protein binding to melanocortin receptors", MOLECULAR ENDOCRINOLOGY, vol. 13, no. 1, January 1999 (1999-01-01), pages 148 - 155, XP002114621 *

Also Published As

Publication number Publication date
AU3964499A (en) 1999-10-18
WO1999050295A2 (fr) 1999-10-07

Similar Documents

Publication Publication Date Title
WO2003006620A3 (fr) Peptides lineaires et cycliques specifiques du recepteur de melanocortine
ZA992877B (en) Process for the preparation of hyndrocarbons from synthesis gas.
ZA983503B (en) Low temperature process for producing synthesis gas.
MXPA03008292A (es) Formas de dosificacion cronoterapeuticas que contienen glucocorticosteroides.
WO1999050295A3 (fr) Analogues de proteine apparentee a l'agouti et leurs methodes d'utilisation
GB2347930B (en) IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof
IL131155A (en) Assay for the measurement of dna synthesis rates
AU4786585A (en) Recovering methane enriched gas from syngas by psa.
WO2003006996A3 (fr) Ligand naturel du recepteur couple aux proteines g chemr23 et utilisations de ce ligand
ATE198047T1 (de) Medizinische präparation, die ein lipophiles edelgas enthält
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001030371A3 (fr) Peptides analgesiants chimeriques
CA2123808A1 (fr) Marqueur electrochimioluminescent pour analyses avec sondes d'adn
NZ231957A (en) Production of methanol from synethesis gas, in the liquid phase
EP1534718A4 (fr) Synthese chimique de reactifs pour couplage peptidique
DK1451224T3 (da) Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
ZA987266B (en) Process for the conversion of a flow containing hydrocarbons by partial oxidation
DE69840035D1 (de) Chimäres protein welches eine intramolekulare chap zur insulinproduktion
DE60105236D1 (de) Reinigungsmethode für eine flüssige Reaktionsmischung aus der Epoxidierung von 1,5,9-Cyclododecatrien
WO2005116198A3 (fr) Procedes de preparation de 1,3-enyne au moyen de catalyseurs de cuivre (i)
EP1129105A4 (fr) Molecules d'adn codant la proteine du recepteur de melanocortine 4 provenant de singe rhesus
WO2004003165A3 (fr) Nouvelles sequences polynucleotidiques et polypeptidiques et leurs utilisations
EP0975689A4 (fr) Reactif d'imidification pour une synthese de polyimides
WO2004028692A3 (fr) Element de support pour analyses diagnostiques
WO2005100386A3 (fr) Récepteur de canine sensible au froid et au menthol 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载